Javascript must be enabled to continue!
Hypersensitivity Myocarditis Due to Antitubercular Drugs in Children
View through CrossRef
Background:
Drug-related hypersensitivity myocarditis is a rare acute hypersensitivity reaction to therapeutic agents. Reports of antitubercular drugs causing hypersensitivity myocarditis are not described in literature.
Methods:
Retrospective chart review of children admitted between January 1, 2016, and March 31, 2019, was conducted to identify children receiving antitubercular drugs who were diagnosed with hypersensitivity myocarditis.
Results:
Three children (2 girls), who had hypersensitivity myocarditis due to antitubercular therapy, were identified. Cases 1 and 2 developed hypersensitivity myocarditis due to rifampicin, and isoniazid-rifampicin combination, respectively, on reintroduction of drugs, while case 3 developed hypersensitivity to streptomycin on first exposure. All children developed symptoms within minutes to hours of starting the offending drugs. Severe myocardial dysfunction leading to shock and pulmonary edema was seen in cases 1 and 3, while case 2 presented with wide QRS complex ventricular rhythm with bradycardia and hypotensive shock. Cases 1 and 2 were treated with steroids. Cases 1 and 3 received intravenous immunoglobulin therapy. First 2 children survived while third died of refractory shock. Total serum IgE levels were elevated in all children (range: 161–3053 kU/L).
Conclusion:
Hypersensitivity myocarditis is a rare but life-threatening adverse effect of antitubercular drugs. Prompt diagnosis of hypersensitivity myocarditis and timely steroid therapy can be lifesaving.
Ovid Technologies (Wolters Kluwer Health)
Title: Hypersensitivity Myocarditis Due to Antitubercular Drugs in Children
Description:
Background:
Drug-related hypersensitivity myocarditis is a rare acute hypersensitivity reaction to therapeutic agents.
Reports of antitubercular drugs causing hypersensitivity myocarditis are not described in literature.
Methods:
Retrospective chart review of children admitted between January 1, 2016, and March 31, 2019, was conducted to identify children receiving antitubercular drugs who were diagnosed with hypersensitivity myocarditis.
Results:
Three children (2 girls), who had hypersensitivity myocarditis due to antitubercular therapy, were identified.
Cases 1 and 2 developed hypersensitivity myocarditis due to rifampicin, and isoniazid-rifampicin combination, respectively, on reintroduction of drugs, while case 3 developed hypersensitivity to streptomycin on first exposure.
All children developed symptoms within minutes to hours of starting the offending drugs.
Severe myocardial dysfunction leading to shock and pulmonary edema was seen in cases 1 and 3, while case 2 presented with wide QRS complex ventricular rhythm with bradycardia and hypotensive shock.
Cases 1 and 2 were treated with steroids.
Cases 1 and 3 received intravenous immunoglobulin therapy.
First 2 children survived while third died of refractory shock.
Total serum IgE levels were elevated in all children (range: 161–3053 kU/L).
Conclusion:
Hypersensitivity myocarditis is a rare but life-threatening adverse effect of antitubercular drugs.
Prompt diagnosis of hypersensitivity myocarditis and timely steroid therapy can be lifesaving.
Related Results
Integrated Bioinformatics analysis and Metabolomic Responses in finding novel therapeutic approach to treat viral myocarditis
Integrated Bioinformatics analysis and Metabolomic Responses in finding novel therapeutic approach to treat viral myocarditis
Abstract
Background
Myocarditis is one of the most common health problems in young people. Despite imaging...
Immune checkpoint inhibitor-associated myocarditis: diagnostic challenges
Immune checkpoint inhibitor-associated myocarditis: diagnostic challenges
Abstract
Background
Immune checkpoint inhibitors (ICIs), which are increasingly used in cancer pharmacotherapy, can induce myoca...
Evolution of Myocarditis Incidence at a Large Healthcare System Before and During COVID-19 Pandemic
Evolution of Myocarditis Incidence at a Large Healthcare System Before and During COVID-19 Pandemic
Abstract
Background
Myocarditis is a recognized complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in...
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Background: Myocarditis and pericarditis cases following Coronavirus 2019 (COVID-19) vaccination were reported worldwide. In Thailand, COVID-19 vaccines were approved for emergency...
P1813Impact of cardiac MRI imaging on detection rates of myocarditis
P1813Impact of cardiac MRI imaging on detection rates of myocarditis
Abstract
Background
The Lake Louise Criteria for the diagnosis of myocarditis by cardiac MRI (CMR) was published in 2009 (JACC A...
Exercise testing in patients with multisystem inflammatory syndrome in children-related myocarditis versus idiopathic or viral myocarditis
Exercise testing in patients with multisystem inflammatory syndrome in children-related myocarditis versus idiopathic or viral myocarditis
AbstractBackground:While most children with multisystem inflammatory syndrome in children have rapid recovery of cardiac dysfunction, little is known about the long-term outcomes r...
Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved
Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved
SummaryBackgroundHypersensitivity reactions to fluoroquinolones seem to be on the increase, especially immediate type reactions.ObjectiveThe aim of this study was to determine whet...
Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines
Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines
ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events w...

